What type of targeted drug is Encorafenib?

Encorafenib is an oral small molecule targeted drug that belongs to the BRAF inhibitor class. It is mainly used to treat advanced malignant tumors carrying BRAF V600E or V600K mutations, especially melanoma. The mechanism of action of canafenib is to inhibit the activity of mutant BRAF protein kinase, thereby blocking the abnormal activation of the MAPK signaling pathway, thereby inhibiting the growth and division of tumor cells. The drug was developed by Array BioPharma and later acquired and promoted by Pfizer.

Compared with otherBRAF inhibitors, canafenib has a longer half-life and higher selectivity, so it can reduce the incidence of adverse reactions to a certain extent. It is often used in combination with MEK inhibitors (such as binimetinib) to enhance the anti-tumor effect and delay the emergence of drug resistance. This combination has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with unresectable or metastatic melanoma harboring BRAF V600E mutations. Its clinical data show that this combination has clear advantages in extending progression-free survival and overall survival.

In addition to melanoma, canafenib has also been studied in other solid tumors with positive BRAF mutations, including colorectal cancer, non-small cell lung cancer and brain glioma. Especially in metastatic colorectal cancer, the combination of canafenib combined with cetuximab (EGFR inhibitor) has shown positive effects in some patients, so its indications have been gradually expanded. Studies have shown that accurate screening of a patient's BRAF mutation status is of great significance in determining whether they are suitable for the use of canafenib.

Overall, canafenib is a BRAF inhibitor with clear targets and good therapeutic effects. It is of great value in the treatment of melanoma and some other BRAF mutation-related cancers. Its combination treatment strategy has become one of the standard regimens for certain tumor types. During use, it is necessary to closely monitor side effects, such as rash, joint pain, high blood pressure, etc., and use the medication rationally under the guidance of a professional doctor.

Reference materials:https://www.braftovi.com/